Displaying 1 - 2 of 2
| Active Ingredient | ATORVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications |
Effective in the treatment of hyper-cholesterolemia and hypertrigly ceridemia. |
| Caution | Headache, diarrhoea, flatulence and mild elevations in liverenzymes. The risk of myopathy and/or rhabdomyolysis is increased when atorvastatin is taken concomitantly with cyclosporine, gemfibrozil, More ... |
| Dose Range |
Adult: Initial dose 10-20mg once daily. The dose may be adjusted at intervals of at least 4 weeks up to a maximum of 80 mg daily . See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of atorvastatin in lactating women. |
| Active Ingredient | ROSUVASTATIN |
| Therapeutic Class | HMG-CoA REDUCTASE INHIBITORS |
| Indications | Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia)’ mixed dyslipidaemia (type Iib), or homozygous familial hypercholesterolaemia in patients who have n More ... |
| Caution | Headache, asthenia, upper respiratory infections, gastrointestinal symptoms, and myalgia have been reported; myopathy has occurred rarely . |
| Dose Range | Adult: 5-20mg once daily . Doses may be titrated to 40mg per day in those who do not meet their lipid lowering goals on 20mg per day. Doses to be increased at intervals of at least 4 weeks. See BDS supply protocols pg. 6. |
| Drug Interactions | |
| Pregnancy | Statins should be avoided in pregnancy (discontinue 3 months before attempting t More ... |
| Breast Feeding | Avoid use of rosuvastatin in lactating women. |